Kentucky Retirement Systems Insurance Trust Fund Purchases Shares of 11,345 DexCom, Inc. (NASDAQ:DXCM)

Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,345 shares of the medical device company's stock, valued at approximately $775,000.

A number of other institutional investors also recently modified their holdings of DXCM. Larson Financial Group LLC grew its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Nia Impact Advisors LLC boosted its position in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after acquiring an additional 140 shares in the last quarter. Level Four Advisory Services LLC increased its stake in DexCom by 1.1% in the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after acquiring an additional 150 shares during the last quarter. Covestor Ltd increased its stake in DexCom by 15.6% in the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after acquiring an additional 150 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on DXCM shares. Mizuho started coverage on DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. The Goldman Sachs Group started coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Canaccord Genuity Group raised their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Robert W. Baird lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Finally, Citigroup restated a "buy" rating and issued a $102.00 target price (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $98.50.

Insider Buying and Selling

In other news, Director Nicholas Augustinos sold 2,618 shares of DexCom stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $81.69, for a total value of $213,864.42. Following the completion of the transaction, the director now directly owns 37,083 shares of the company's stock, valued at approximately $3,029,310.27. This trade represents a 6.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 10,000 shares of the company's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the sale, the executive vice president now owns 95,602 shares in the company, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold 25,724 shares of company stock valued at $2,157,034 over the last quarter. Insiders own 0.32% of the company's stock.

DexCom Trading Up 1.4%

Shares of DXCM traded up $1.22 during mid-day trading on Friday, reaching $86.26. 349,199 shares of the company were exchanged, compared to its average volume of 4,369,185. The business has a 50 day simple moving average of $81.34 and a two-hundred day simple moving average of $79.54. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The stock has a market capitalization of $33.82 billion, a PE ratio of 64.22, a PEG ratio of 1.81 and a beta of 1.46. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the company posted $0.32 EPS. The business's revenue for the quarter was up 12.5% compared to the same quarter last year. On average, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.